Literature DB >> 2663021

Structural requirements of lipid A for endotoxicity and other biological activities.

H Takada1, S Kotani.   

Abstract

For the past ten years, several groups were engaged in synthetic studies of lipid A, namely the lipid portion of bacterial lipopolysaccharides (LPS) that has been assumed to be the bioactive center of LPS, but has not been unanimously approved. Among them, Shiba, Kusumoto, and colleagues, Osaka, Japan have synthesized most energetically and successfully a variety of counterparts of lipid As, biosynthetic lipid A precursors, and their analogs. The endotoxic and related bioactivities of these synthetic compounds were studied by Japanese and German groups, including ours. In 1985, one of the compounds, having an acylation and phosphorylation pattern in beta(1-6)-D-glucosamine disaccharide which was proposed for Escherichia coli F515 lipid A was found to be exhibit full endotoxic and related bioactivities identical to those of the bacterial product. The study was extended by synthesis and examination of bioactivities of variously acylated D-glucosamine di- and monosaccharide phosphates, which correspond to structural components of lipid As, and their analogs or derivatives. Thus, structural requirements have been fairly well elucidated. In this article, first we will review the progress of synthetic and biological studies, with particular emphasis on chemical structure--bioactivities relationships of lipid As, and then we will discuss possible usefulness of some less or nontoxic lipid A-related synthetic compounds in clinical and preventive medicine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663021     DOI: 10.3109/10408418909104475

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  36 in total

1.  Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2.

Authors:  Umeharu Ohto; Koichi Fukase; Kensuke Miyake; Toshiyuki Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-24       Impact factor: 11.205

Review 2.  Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?

Authors:  Nicole K Brogden; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2011-07-05       Impact factor: 5.283

3.  Induction of early gene expression in murine macrophages by synthetic lipid A analogs with differing endotoxic potentials.

Authors:  P Y Perera; C L Manthey; P L Stütz; J Hildebrandt; S N Vogel
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 4.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

5.  Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides.

Authors:  P J Baker; T Hraba; C E Taylor; P W Stashak; M B Fauntleroy; U Zähringer; K Takayama; T R Sievert; X Hronowski; R J Cotter
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

6.  Comparison of lipids A of several Salmonella and Escherichia strains by 252Cf plasma desorption mass spectrometry.

Authors:  D Karibian; C Deprun; M Caroff
Journal:  J Bacteriol       Date:  1993-05       Impact factor: 3.490

7.  MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation.

Authors:  Jianmin Meng; Egil Lien; Douglas T Golenbock
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

8.  L-rhamnose inhibits proliferation of murine splenocytes by the lipopolysaccharide and polysaccharide moiety of Shigella dysenteriae type 1 lipopolysaccharide.

Authors:  T Biswas; S Roy; K K Banerjee
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

9.  Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines.

Authors:  J Goldstein; T Hoffman; C Frasch; E F Lizzio; P R Beining; D Hochstein; Y L Lee; R D Angus; B Golding
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

10.  De novo design of potent antimicrobial peptides.

Authors:  V Frecer; B Ho; J L Ding
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.